Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Equity (2019 - 2025)

Historic Return on Equity for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.42%.

  • BridgeBio Pharma's Return on Equity rose 300.0% to 0.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.42%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.39% for FY2024, which is 1200.0% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Return on Equity is 0.42%, which was up 300.0% from 0.44% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Return on Equity peaked at 4.09% during Q1 2021, and registered a low of 0.39% during Q4 2024.
  • For the 5-year period, BridgeBio Pharma's Return on Equity averaged around 0.76%, with its median value being 0.49% (2023).
  • In the last 5 years, BridgeBio Pharma's Return on Equity soared by 47600bps in 2021 and then tumbled by -34200bps in 2022.
  • BridgeBio Pharma's Return on Equity (Quarter) stood at 0.78% in 2021, then plummeted by -36bps to 0.49% in 2022, then grew by 7bps to 0.53% in 2023, then fell by -26bps to 0.39% in 2024, then grew by 7bps to 0.42% in 2025.
  • Its last three reported values are 0.42% in Q3 2025, 0.44% for Q2 2025, and 0.42% during Q1 2025.